| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $608K | +22.6% | +4242.9% |
| SG&A Expense | $827K | -13.9% | +124.1% |
| Operating Income | -$1.4M | +1.4% | -274.7% |
| Net Income | -$1.4M | +1.7% | -33.5% |
| EPS (Basic) | -$0.07 | +12.5% | +30.0% |
| EPS (Diluted) | -$0.07 | +12.5% | +30.0% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $5.6M | +83.8% | — |
| Current Assets | $6.7M | +37.5% | +40.4% |
| Total Assets | $8.1M | +20.9% | +61.2% |
| Current Liabilities | $402K | -40.5% | -76.0% |
| Stockholders' Equity | $7.7M | +27.8% | +130.0% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$2.4M | — | — |
| Financing Cash Flow | $6.7M | — | — |